Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival
Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response
FDA Grants Accelerated Approval to Imbruvica
Two Papers Evaluate CyberKnife Survival Rates and Tolerability
ANG1005 Demonstrates Activity In Patients with Brain Metastases
MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues
AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial
NCI CTEP Approved Trials For the Month of November
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital
